These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8497493)

  • 1. Induction of apoptosis in blood cells from a patient with acute myelogenous leukemia by SC41661A, a selective inhibitor of 5-lipoxygenase.
    Anderson KM; Levin J; Jajeh A; Seed T; Harris JE
    Prostaglandins Leukot Essent Fatty Acids; 1993 Apr; 48(4):323-6. PubMed ID: 8497493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis.
    Anderson KM; Seed T; Plate JM; Jajeh A; Meng J; Harris JE
    Leuk Res; 1995 Nov; 19(11):789-801. PubMed ID: 8551795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic changes of apoptosis induced in human chronic myelogenous leukemia "blast" cells by SC41661A (Searle), a selective inhibitor of 5-lipoxygenase.
    Anderson KM; Seed TM; Peng J; Jajeh A; Meng J; Harris JE
    Scanning Microsc; 1994; 8(3):675-84; discussion 684-6. PubMed ID: 7747166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective 5-lipoxygenase inhibitor A63162 reduces PC3 proliferation and initiates morphologic changes consistent with secretion.
    Anderson KM; Seed T; Ondrey F; Harris JE
    Anticancer Res; 1994; 14(5A):1951-60. PubMed ID: 7847833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death.
    Anderson KM; Seed T; Vos M; Mulshine J; Meng J; Alrefai W; Ou D; Harris JE
    Prostate; 1998 Nov; 37(3):161-73. PubMed ID: 9792133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells.
    Rowley PT; Keng PC; Kosciolek BA
    Leuk Res; 1996 Jun; 20(6):473-80. PubMed ID: 8709619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ETYA, a pleotropic membrane-active arachidonic acid analogue affects multiple signal transduction pathways in cultured transformed mammalian cells.
    Anderson KM; Ondrey F; Harris JE
    Clin Biochem; 1992 Feb; 25(1):1-9. PubMed ID: 1551235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
    Gewirtz AM
    Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
    Szczylik C; Skórski T; Malaguarnera L; Hetman J; Chen ST; Calabretta B
    Folia Histochem Cytobiol; 1996; 34(3-4):129-34. PubMed ID: 8967957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
    Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that endogenous generation of leukotrienes does not regulate proliferation of malignant hemopoietic cell lines.
    Ayyub Khan M; Tateson JE; Hoffbrand AV; Wickremasinghe RG
    Leuk Res; 1993 Mar; 17(3):241-5. PubMed ID: 8450672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
    Szczylik C; Skorski T; Nicolaides NC; Manzella L; Malaguarnera L; Venturelli D; Gewirtz AM; Calabretta B
    Science; 1991 Aug; 253(5019):562-5. PubMed ID: 1857987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.
    Rosti V; Bergamaschi G; Ponchio L; Cazzola M
    Leukemia; 1992 Jan; 6(1):1-7. PubMed ID: 1736009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5,8,11,14-eicosatetraynoic acid inhibits PC3 DNA synthesis and cellular proliferation, in part due to its 5'-lipoxygenase activity.
    Anderson KM; Harris JE
    Clin Physiol Biochem; 1990; 8(6):308-13. PubMed ID: 2132166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides.
    Lanza F; Bi S; Moretti S; Castoldi G; Goldman JM
    Br J Haematol; 1995 May; 90(1):8-14. PubMed ID: 7786800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
    Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
    Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.